Key result
Before and during cardiopulmonary bypass, there was a poor correlation (r = 0.38) between the High Dose Thrombin Time and the Activated Clotting Time.
Why the study?
Comparative ACT/HiTT assays in cardiac surgery patients are recommended by the HiTT test manufacturer, but the correlation and target values between HiTT and ACT during CPB are uncertain.
Does High Dose Thrombin Time (HiTT) correlate with Activated Clotting Time (ACT) for monitoring heparin effects during cardiopulmonary bypass?
Observational (n=20)
No
Does High Dose Thrombin Time (HiTT) correlate with Activated Clotting Time (ACT) for monitoring heparin effects during cardiopulmonary bypass?
A target HiTT of 190 seconds does not guarantee an adequate ACT of 480 seconds during cardiopulmonary bypass, suggesting comparative assays should be done for each individual patient.
In this study we compared the High Dose Thrombin Time (HiTT) with the Activated Clotting Time (ACT) during cardiopulmonary bypass (CPB) in non-aprotinin treated patients. On the advice of the HiTT test manufacturer each institution should perform comparative ACT/HiTT assays in the cardiac surgery population. In previous tests our target ACT value of 480 seconds corresponds with a mean HiTT value of 190 seconds. Our results showed that after heparinization (300-400 IU/kg body weight) 8 out of 20 patients did not reach the target ACT of 480 seconds, while the HiTT results in those 8 patients were higher than our target time of 190 seconds. Four heparin pretreated patients who received 400 IU/kg heparin, had relatively low ACT values (467 +/- 14 sec.) and high HiTT values (324 +/- 47 sec.). Before and during CPB there was a poor correlation between the HiTT and ACT (r = 0.38). The results of this study show that for the individual patient the target HiTT of 190 seconds is no guarantee for reaching an adequate ACT of 480 seconds. Although the HiTT may be a very useful assay for monitoring heparin effects during CPB, the determination of the target time can be a point of discussion. In contrast of the advice of the manufacturer we therefore suggest that comparative ACT/HiTT assay should be done in every individual patient to determine a safe target HiTT time, instead of the whole group of patients.
No takes yet. Share an insight, caveat, or question.
A 1999 study conducted an observational in Elective cardiac surgery requiring cardiopulmonary bypass (n=20). High Dose Thrombin Time (HiTT) vs. Activated Clotting Time (ACT) was evaluated on Correlation between HiTT and ACT before and during cardiopulmonary bypass (r = 0.38). Before and during cardiopulmonary bypass, there was a poor correlation (r = 0.38) between the High Dose Thrombin Time and the Activated Clotting Time.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: